Illumina (ILMN) Faces A German Recall Order, Is The Stock Fully Priced?

Simply Wall St.

07/23

A German court ruling against Illumina (ILMN) over alleged patent infringement by its DNA sequencing systems has forced an injunction and recall in Germany, placing legal, operational, and ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2653793840"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653793840\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653793840?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-07-23 03:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653793840","market":"us","top_or_hot":-1,"title":"Illumina (ILMN) Faces A German Recall Order, Is The Stock Fully Priced?","media":"Simply Wall St.","content":"<div>\n<p>A German court ruling against Illumina (ILMN) over alleged patent infringement by its DNA sequencing systems has forced an injunction and recall in Germany, placing legal, operational, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-faces-a-german-recall-order-is-the-stock-fully\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Illumina (ILMN) Faces A German Recall Order, Is The Stock Fully Priced?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIllumina (ILMN) Faces A German Recall Order, Is The Stock Fully Priced?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-23 03:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-faces-a-german-recall-order-is-the-stock-fully><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A German court ruling against Illumina (ILMN) over alleged patent infringement by its DNA sequencing systems has forced an injunction and recall in Germany, placing legal, operational, and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-faces-a-german-recall-order-is-the-stock-fully\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-faces-a-german-recall-order-is-the-stock-fully","article_id":"2653793840","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/illumina-ilmn-faces-a-german-recall-order-is-the-stock-fully","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2653793840","pubTimestamp":1784748469,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"A German court ruling against Illumina (ILMN) over alleged patent infringement by its DNA sequencing systems has forced an injunction and recall in Germany, placing legal, operational, and reputational risks in sharper focus for investors.\nSee our latest analysis for Illumina.\nThe legal setback in Germany comes after a strong run in Illumina’s stock, with a 30-day share price return of 18.90% and a 90-day share price return of 47.53%. However, the 1-year total shareholder return of 88.70%...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","GNOM":"Global X Genomics & Biotechnology ETF","BK4121":"生命科学工具和服务","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","ILMN":"Illumina","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","GNMX":"Corgi Genomics & Precision Medicine ETF"},"translate_title":"Illumina (ILMN) 面临德国召回令，该股已全部定价吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNMX":0.6,"GNOM":0.6,"ILMN":1.5},"content_text":"A German court ruling against Illumina (ILMN) over alleged patent infringement by its DNA sequencing systems has forced an injunction and recall in Germany, placing legal, operational, and reputational risks in sharper focus for investors. See our latest analysis for Illumina. The legal setback in Germany comes after a strong run in Illumina’s stock, with a 30-day share price return of 18.90% and a 90-day share price return of 47.53%. However, the 1-year total shareholder return of 88.70% contrasts with a 5-year total shareholder return that is down 59.26%, suggesting recent momentum has picked up after a weak longer-term stretch. If this kind of legal and technology driven story has your attention, it could be a good moment to see what else is happening across genomics and biotech by checking a healthcare focused AI screener like 39 healthcare AI stocks. Illumina’s core sequencing business and data partnerships are drawing fresh attention, yet the stock has already run hard in recent months while legal and pricing questions build in the background. Is that business strength actually available at a reasonable valuation today? AdvertisementMost Popular Narrative: 30.8% Overvalued Comparing Illumina’s narrative fair value of $147.17 to the last close at $192.53, the most widely followed storyline sees the stock trading well ahead of that anchor, and it builds that view off detailed assumptions about clinical sequencing and future cash flows.  Strong and resilient growth in clinical applications, especially oncology, genetic disease testing, and reproductive health, continues to expand as genomic technologies become the standard of care. This supports both recurring revenues from consumables and long-term earnings visibility.  Read the complete narrative. Read the complete narrative. Want to see what is baked into that higher price? The narrative leans on steady revenue expansion, firmer margins, and a leaner share count to support its cash flow math. Result: Fair Value of $147.17 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Illumina’s story still hinges on research budgets and China exposure. Softer demand or tighter regulations could quickly challenge those upbeat clinical and cash flow assumptions. Find out about the key risks to this Illumina narrative. Another View: Illumina Through a P/E Lens The first narrative framed Illumina as 30.8% overvalued relative to a fair value of $147.17, but the market is sending a different signal if you focus on earnings. At $192.53, the stock trades on a P/E of 34.1x, which is lower than the Global Life Sciences industry average of 38.7x, yet higher than the peer average of 31.9x and above a fair ratio of 23.2x that the market could eventually move toward. That mix of relative discount to the wider industry, premium to peers, and gap to the fair ratio raises a simple question for investors: is today’s price leaning more toward opportunity or valuation risk? See what the numbers say about this price in our valuation breakdown, including how it compares to the fair ratio and peer group, in the See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ILMN P/E Ratio as at Jul 2026Next Steps With Illumina attracting both concern and optimism, this is a good moment to move fast, review the full picture, and weigh the 3 key rewards and 2 important warning signs. Looking for more investment ideas beyond Illumina? If Illumina has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with other stocks that match clear, data driven criteria.  Spot potential value opportunities early by scanning 50 high quality undervalued stocks that pair quality fundamentals with prices that may not fully reflect them yet. Prioritise resilience in choppy markets by checking 81 resilient stocks with low risk scores that score well on financial strength and business stability. Hunt for tomorrow’s potential standouts by browsing the screener containing 20 high quality undiscovered gems before they appear on everyone else’s radar.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}